2.87
0.16 (5.9%)
0.16 (5.9%)
Upgrade to Real-Time
Afterhours (Closed)
| Volume | 105,710 |
|
|||||
| News | - | ||||||
| Day High | 2.90 | Low High |
|||||
| Day Low | 2.72 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Scynexis Inc | SCYX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.16 | 5.9% | 2.87 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.72 | 2.72 | 2.90 | 2.87 | 2.71 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 576 | 105,710 | $ 2.82 | $ 297,967 | - | 1.70 - 8.10 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:51:39 | 50 | $ 2.87 | USD |
Period:
Draw Mode:
Scynexis Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 93.50M | 32.58M | 25.56M | $ 13.16M | $ -3.79M | -1.03 | -2.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 120.00k | 2.30% |
Scynexis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SCYX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.77 | 2.95 | 2.64 | 2.76 | 169,853 | 0.10 | 3.61% |
| 1 Month | 1.92 | 2.95 | 1.82 | 2.38 | 177,428 | 0.95 | 49.48% |
| 3 Months | 2.10 | 2.95 | 1.70 | 2.15 | 127,784 | 0.77 | 36.67% |
| 6 Months | 4.80 | 5.1475 | 1.70 | 3.04 | 223,099 | -1.93 | -40.21% |
| 1 Year | 6.42 | 8.10 | 1.70 | 4.84 | 251,103 | -3.55 | -55.3% |
| 3 Years | 1.02 | 11.30 | 0.50 | 3.59 | 483,416 | 1.85 | 181.37% |
| 5 Years | 1.55 | 11.30 | 0.35 | 2.70 | 494,777 | 1.32 | 85.16% |
Scynexis Description
| SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. |